ET collaborates with
Terumo Blood Cell Technologies

Upcoming development and commercialization of a novel therapeutic apheresis treatment for Sepsis & acute kidney injury (AKI)

Learn More

NEWSROOM

ETI Awarded $1.7 million by NIH

For XGAL-3s Apheresis Large Animal Safety Study

Learn More

_

mission + target
Eliaz Therapeutics is creating a groundbreaking targeted apheresis device aimed at eliminating the root cause of numerous diseases.

Our mission is to change the course of life-threatening diseases to improve survival and prevent long-term disease and disability, starting with Sepsis and Sepsis associated Acute Kidney Injury (SA-AKI), the leading cause of death globally.

The Problem
Addressing the Global Health Challenges of Sepsis and Acute Kidney Injury (AKI)

Sepsis is a major health issue that affects millions of people around the world every year. It's the leading cause of death globally, impacting about 49 million people and causing 11 million deaths annually. In the United States alone, sepsis affects over 2 million people each year, leading to long hospital stays and intensive care. The cost of treating sepsis in the U.S. tops $62 billion annually, making it not only a health crisis but a significant financial burden on our healthcare system.

Despite its prevalence, current treatments for sepsis are limited to stop the devastating inflammatory cascade of sepsis. This highlights a critical need for new treatments that can actually address the damaging mechanism of sepsis, improve patient outcomes, and reduce healthcare costs.

Acute Kidney Injury (AKI) is another serious condition that affects nearly 4 million Americans each year. Treating AKI is very expensive, costing up to $24 billion annually. For those with severe cases that require dialysis, hospital costs can soar to $42,000 per visit. These high costs show how important it is to find better ways to manage and treat AKI, to help both patients and the healthcare system.

Learn More

ETI's Solution: XGal-3® Device

Eliaz Therapeutics is pioneering a groundbreaking medical device designed to selectively remove galectin-3 (Gal-3) from the bloodstream.

Galectin-3
is a crucial driver of immune dysregulation, inflammation and fibrosis across various acute and chronic conditions.  Gal-3 blood levels  in  Sepsis and Acute Kidney Injury (AKI) correlate with disease outcome-   mortality and multi organ failure. Studies in sepsis animal models show that removal of Gal-3 via apheresis significantly reduces  the mortality from   Sepsis, as well as multi organ damage.

XGAL-3® is a pioneering patented platform technology that selectively removes the root cause - Galectin-3 from the bloodstream through targeted therapeutic apheresis.

Find out how we have developed the technology to target and remove Gal-3 directly from the bloodstream.

Learn More
Target
What is Galectin-3?

The Hidden Cause of Chronic Disease

Galectin-3 (Gal-3) is a protein that is naturally produced by our bodies. However, its levels can increase over time due to factors like stress, injury, and aging. Extensive research, spanning over 3,000 studies, has shown that elevated Gal-3 levels play a significant role in a variety of health problems. Many common chronic conditions that affect us and our loved ones have been linked to the harmful effects of this protein.

What are some of the health indications caused by Galectin-3?

  • Sepsis
  • Kidney Disease
  • Inflammation
  • Heart Disease
  • Fibrosis
  • Cancer
How do we remove Galectin-3 from our bodies?
TECHNOLOGY

XGal-3® Column for Removing the Root Cause

The XGal-3 Apheresis Column:
The column is designed to selectively remove Galectin-3, the harmful protein linked to chronic conditions, from the patient's bloodstream.

Engineered for Effectiveness:
The column features a custom-designed molecule that efficiently binds and removes Galectin-3 with high efficacy.
Seamless Integration:
The XGal-3 column is designed to be compatible with existing hospital protocols, allowing for easy adoption and use by healthcare providers.



Patient-safe
Nothing goes into the patient's body.
Single-use
100% disposable with effective removal.
Easy Adoption
Fits into existing apheresis systems.

How it works

Join us in fighting life-threatening diseases.
Learn more about our current investment programs.
CONTACT US